Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; water for injections; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; dibasic sodium phosphate; sodium chloride; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; sodium chloride; monobasic sodium phosphate monohydrate; water for injections; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: sodium chloride; monobasic sodium phosphate monohydrate; dibasic sodium phosphate; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 40 microgram/ml - injection, solution - excipient ingredients: water for injections; polysorbate 80; sodium chloride; monobasic sodium phosphate monohydrate; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: sodium chloride; polysorbate 80; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; dibasic sodium phosphate; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: polysorbate 80; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; water for injections; sodium chloride - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 25 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; polysorbate 80; water for injections; sodium chloride; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.